Our CEO Bjoern Schelter wrote for PharmaTimes exploring the role of technology in transforming brain health. He notes more than a century after Alzheimer’s Disease was first identified, reliable and early diagnosis remains a challenge. Simple diagnostic tests which aren’t language-dependent will enable much earlier testing and harnessing digital technology will offer higher accuracy and reliability.
Accessible gamified diagnostic tools may offer reassurance to those who don’t have the condition and allow those with early warning signs to seek medical advice and potentially make lifestyle adjustments that may prevent significant symptoms from developing in later life.
Read Bjoern’s article here.
